CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer

20260 citationsJournal Article

Authors

Francesca Jackson-Spence · Queen Mary University of London

James Larkin · Royal Marsden Hospital

P. Patel · Nottingham University Hospitals NHS Trust

Begoña P. Valderrama · Hospital Universitario Virgen del Rocío

Alejo Rodriguez-Vida · Hospital Del Mar

Hilary Glen · Beatson West of Scotland Cancer Centre

Fiona Thistlethwaite

Abstract

Savolitinib plus durvalumab shows OS in <i>MET</i>-driven PRC, supporting the ongoing SAMETA RIII trial (ClinicalTrials.gov identifier: NCT05043090). ctDNA may be a useful predictive biomarker.

Topics & Keywords

Renal cell carcinoma treatment Cancer Genomics and Diagnostics Cancer Immunotherapy and Biomarkers

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

DOI: 10.1200/jco-25-01840

Field-Weighted Citation Impact: 0.00